GlobeNewswire Inc.··NaDay One Biopharmaceuticals Posts 172% Revenue Growth on OJEMDA Sales Strength
Day One Biopharmaceuticals reports 172% revenue growth to $155.4M, driven by OJEMDA sales strength. Company acquires Mersana Therapeutics to expand pipeline.
DAWNclinical trialsrevenue growth